Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

One Health Group backs Scunthorpe healthcare expansion

Scunthorpe's healthcare evolution is attracting investors as One Health Group plans a new surgical hub, enhancing patient care and driving financial growth...

Severe influenza demands a smarter approach

Severe influenza is a critical health challenge that demands innovative solutions. Learn how advanced technologies are transforming care for high-risk populations...

Targeting inflammation with precision in viral challenge trials

Discover hVIVO's groundbreaking studies on immunomodulators presented at ESCMID 2025, revealing insights into viral infections and host immune responses...

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP)...

Nuformix advancing IPF treatment with NXP002 orphan drug designation (LON:NFX)

Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...

AstraZeneca Plc Calquence combo approved in EU for first-line MCL

AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...

Aptamer adapts Alzheimer’s test to ELISA and signs royalty deal

Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection...

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...

Nuformix advances NXP002 as EMA backs Orphan Drug status

Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...

Why asthma shouldn’t stop you investing in the power of exercise

Asthma affects millions, but with the right management and support from FluCamp, individuals can embrace exercise for better health. Discover more today!..

Unlocking CAR-T’s full potential with POLB 001

Discover how Poolbeg Pharma's POLB 001 is transforming CAR-T cell therapies, aiming to reduce cytokine release syndrome and enhance patient safety in cancer treatment...

Nuformix Plc, EMA Backs Orphan Status for NXP002 in Pulmonary Fibrosis Breakthrough (Video)

Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support..

Haleon Plc Q1 2025: £2.85bn revenue, 3.5% organic growth

Haleon plc has released its Q1 trading statement for 2025, with a presentation and Q&A session led by CFO Dawn Allen scheduled for April 30...

GSK Plc delivers strong Q1 2025 with profit and Specialty Medicines growth

GSK PLC reports strong Q1 2025 results, driven by Specialty Medicines growth and significant R&D investments, highlighting confidence in future performance...

Nuformix secures positive EMA opinion for orphan drug status in IPF

Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...

Aptamer licences Optimer binders for swine vaccines

Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health...

One Health Group accelerates expansion amid soaring demand

One Health Group is transforming healthcare with impressive growth and a commitment to tackling NHS waiting times, solidifying its role as a trusted provider...

Advancing RSV research with the New RSV-B London strain

Discover hVIVO's groundbreaking RSV-B London strain, a pivotal advancement in respiratory virus research, enhancing vaccine and antiviral development for RSV...

AstraZeneca Plc reports revenue up 10%, strong pipeline progress

AstraZeneca Plc's Q1 2025 results reveal strong growth and a focus on pipeline delivery, setting the stage for ambitious goals leading to 2030...

Nuformix updates Registered Office and Company Secretary

Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...
Search

Funds

Health

One Health Group backs Scunthorpe healthcare expansion

Scunthorpe's healthcare evolution is attracting investors as One Health Group plans a new surgical hub, enhancing patient care and driving financial growth...

Severe influenza demands a smarter approach

Severe influenza is a critical health challenge that demands innovative solutions. Learn how advanced technologies are transforming care for high-risk populations...

Targeting inflammation with precision in viral challenge trials

Discover hVIVO's groundbreaking studies on immunomodulators presented at ESCMID 2025, revealing insights into viral infections and host immune responses...

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP)...

Nuformix advancing IPF treatment with NXP002 orphan drug designation (LON:NFX)

Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...

AstraZeneca Plc Calquence combo approved in EU for first-line MCL

AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...

Aptamer adapts Alzheimer’s test to ELISA and signs royalty deal

Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection...

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...

Nuformix advances NXP002 as EMA backs Orphan Drug status

Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...

Why asthma shouldn’t stop you investing in the power of exercise

Asthma affects millions, but with the right management and support from FluCamp, individuals can embrace exercise for better health. Discover more today!..

Unlocking CAR-T’s full potential with POLB 001

Discover how Poolbeg Pharma's POLB 001 is transforming CAR-T cell therapies, aiming to reduce cytokine release syndrome and enhance patient safety in cancer treatment...

Nuformix Plc, EMA Backs Orphan Status for NXP002 in Pulmonary Fibrosis Breakthrough (Video)

Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support..

Haleon Plc Q1 2025: £2.85bn revenue, 3.5% organic growth

Haleon plc has released its Q1 trading statement for 2025, with a presentation and Q&A session led by CFO Dawn Allen scheduled for April 30...

GSK Plc delivers strong Q1 2025 with profit and Specialty Medicines growth

GSK PLC reports strong Q1 2025 results, driven by Specialty Medicines growth and significant R&D investments, highlighting confidence in future performance...

Nuformix secures positive EMA opinion for orphan drug status in IPF

Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...

Aptamer licences Optimer binders for swine vaccines

Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health...

One Health Group accelerates expansion amid soaring demand

One Health Group is transforming healthcare with impressive growth and a commitment to tackling NHS waiting times, solidifying its role as a trusted provider...

Advancing RSV research with the New RSV-B London strain

Discover hVIVO's groundbreaking RSV-B London strain, a pivotal advancement in respiratory virus research, enhancing vaccine and antiviral development for RSV...

AstraZeneca Plc reports revenue up 10%, strong pipeline progress

AstraZeneca Plc's Q1 2025 results reveal strong growth and a focus on pipeline delivery, setting the stage for ambitious goals leading to 2030...

Nuformix updates Registered Office and Company Secretary

Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...
Search

Funds

Health

FTSE 100

Funds